Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07017270
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT07017270
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07017270. Randomized; no masking; primary purpose treatment. Start 2025-11-27 (actual); primary completion 2027-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
- Acronym
- GUARD-1
- Condition
- Kidney Disease, Chronic
- Condition
- Diabetes
- Condition
- Dialysis
- Condition
- End Stage Kidney Disease (ESRD)
- Intervention (Drug)
- Semaglutide Pen
- Lead sponsor
- Unity Health Toronto
Record details
- Record id
cardio:ct-nct07017270- Content hash
97fd1e3585d5b6a9f5cb803a774816c6ceb54c8c1e152dba93e3c4ebf36aa93e